文献速递淋巴瘤

套细胞淋巴瘤:布鲁顿酪氨酸激酶靶向治疗策略的最佳治疗

Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches.
PubMed 文献 · J Clin Oncol · 2025-05-29

套细胞淋巴瘤(MCL)总体生存有限,复发时共价布鲁顿酪氨酸激酶(cBTK)抑制剂单药高效且为既定标准。本综述汇总近期多项II期及随机II/III期试验数据,这些数据强烈提示一线整合cBTK抑制剂可获益,作者讨论证据强度与质量并提出基于未来一线可及性的治疗算法。

要点

  • 复发MCL中cBTK抑制剂单药为既定标准治疗。
  • 近期II期及随机II/III期试验显示一线加用cBTK抑制剂获益。
  • 作者基于未来一线可及性提出整合cBTK抑制剂的治疗算法。

核心结论

  • 近期数据强烈提示一线整合共价BTK抑制可获益,作者据此提出治疗算法。

研究设计与样本

  • 综述,汇总近期多项II期及随机II/III期临床试验数据。

主要发现

  • 复发MCL中cBTK抑制剂单药高效且为既定标准。
  • 多项II期及随机II/III期试验显示一线加用cBTK抑制剂获益。

临床怎么用

  • 作者基于未来一线可及性提出整合cBTK抑制剂的治疗算法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL) represents a relatively uncommon, heterogeneous lymphoma associated with limited overall survival. Targeting of the B-cell receptor pathway in relapsed disease with covalent Bruton tyrosine kinase (cBTK) inhibition has been demonstrated to be highly effective with cBTK inhibitor monotherapy, an established standard of care in relapsed MCL. This review summarizes the recent data strongly suggesting a role for the integration of covalent BTK inhibition in the first-line treatment setting, after the recent presentation and publication of multiple phase II and randomized phase II/III clinical trials demonstrating benefit for the addition of cBTK inhibitors first line. The authors discuss herein the strength and quality of the evidence for therapeutic strategies integrating cBTK inhibitors first line and proposal treatment algorithms on the basis of assumed future availability of this highly active small molecules first line in the near future.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Eyre TA, Cheah CY, Sarkozy C, et al. Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches. J Clin Oncol. 2025. PMID: 40440566. doi:10.1200/JCO-25-00146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。